CellXplore has generated proprietary methods for probing the ubiquitin/ proteasome system. These technologies reflect a number of noteworthy innovations, including affinity matrices that can specifically isolate ubiquitinated substrates, as well as catalytically active proteasomes. Significantly, these matrices eliminate uninformative proteins, and specifically identify the low-abundance regulatory factors that are likely to contain biomarkers.

Candidate biomarkers that were previously identified are being tested in accessible body fluids including blood and urine. These technologies represent a platform for characterizing a broad range of cancers, and aberrant growth conditions.